Xu and colleagues reported a real-world efficacy of lenvatinib combined with various PD-1 inhibitors (nivolumab, pembrolizumab, camrelizumab, sintilimab, tislelizumab, and toripalimab) in the treatment of unresectable HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.